{
    "symbol": "APTX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-08 21:46:05",
    "content": " Given the huge need for novel therapies in these disease areas, a positive signal should enable us to move into a larger study that we hoped could serve as a pivotal trial and what position NYX-458 is one of the few late-stage development programs for Parkinson's cognitive impairment. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. I think what we would like to, if that were to transpire, I think we would like to see there be some translation of that effect on one or two sub scores or domains into a functional improvement, because I think that's probably how FDA would look at it, which is to say, the rubber meets the road, essentially, and improving the patient's activities of daily living, if that can be done with an effect on a single domain are just a couple of domains, then that could be interesting. Your line is now open. Your line is now open."
}